Advanced Pharmacology for Prescribers 1st Edition Luu Kayingo Latest
Edition, 2024
, Table of Contents
Chapter 1: An Introduction to Evidence-Based Clinical Practice Guidelines............................................... 4
Chapter 2: Pharmacokinetics /Chapter3: Pharmacodynamics .................................................................... 13
Chapter4: Pharmacogenetics and Pharmacogenomics ................................................................................ 25
,Chapter 5: Pharmacology Across the Life Span ......................................................................................... 29
Chapter 6: Drug-Therapy Prescribing in Special Populations .................................................................... 36
Chapter 7: Drug Development and Approval ............................................................................................. 45
Chapter 8-Chapter 10: Foundations of Prescription Writing Chapter 9: Responsible Controlled-Substance
Prescribing Chapter 10: Antibiotic Stewardship......................................................................................... 50
Chapter 11: Applied Calculations for Prescribing ...................................................................................... 58
Chapter 12-: Promoting Adherence With Pharmacotherapy II: System-Specific and Patient-Focused
Prescribing Chapter 13: Pharmacotherapy for Ear, Nose, Mouth, and Throat Conditions /Chapter 14:
Pharmacotherapy for Eye Conditions ......................................................................................................... 66
Chapter 15: Pharmacotherapy for Skin Conditions .................................................................................... 73
Chapter 16: Pharmacotherapy for Neurologic Conditions .......................................................................... 80
Chapter 17: Pharmacotherapy for Cardiovascular Conditions .................................................................... 92
Chapter 18: Pharmacotherapy for Respiratory Conditions ....................................................................... 104
Chapter 19: Pharmacotherapy for Gastrointestinal Conditions and Conditions Requiring Nutritional ... 114
Support ...................................................................................................................................................... 114
Chapter 20: Pharmacotherapy for Genitourinary Conditions ................................................................... 124
Chapter 21: Pharmacotherapy for Renal, Acid–Base, Fluid, and Electrolyte Disorders .......................... 130
Chapter 22: Pharmacotherapy for Musculoskeletal and Rheumatologic Conditions ................................ 142
Chapter 23: Therapeutic Applications of Immunology and Vaccines ...................................................... 153
Chapter 24: Pharmacotherapy for Endocrine Disorders ........................................................................... 158
Chapter 25: Pharmacotherapy for Hematologic Disorders ....................................................................... 171
Chapter 26: Hematology/Oncology and Supportive Care for the Nononcologist..................................... 186
Chapter 27: Pharmacotherapy Related to Women’s Health Conditions ................................................... 194
Chapter 28: Pharmacotherapy Related to Men’s Health Conditions ........................................................ 208
Chapter 29: Pharmacotherapy Related to Transgender Care .................................................................... 214
Chapter 30: Antimicrobial Pharmacotherapy............................................................................................ 221
Chapter 31: Antiretroviral Pharmacotherapy ............................................................................................ 232
Chapter 32: Psychopharmacology and Integrative Health: Combined Treatment of Psychiatric and
Neurocognitive Conditions ....................................................................................................................... 245
Chapter 33: Pharmacotherapy for Pain Management ............................................................................... 254
Chapter 34: Substance Use Disorder III: Health Promotion and Maintenance ......................................... 264
Chapter 35: Over-the-Counter Medications .............................................................................................. 280
Chapter 36: Pharmacotherapy for Obesity ................................................................................................ 287
, Chapter 1: An Introduction to Evidence-Based Clinical Practice Guidelines
MULTIPLE CHOICE
• What is the primary purpose of the nursing assessment?
A. Identifying underlying pathologic conditions
B. Assisting the physician in identifying medical conditions
C. Determining the patients mental status
D. Exploring patient responses to health problems
ANS: D
A nursing assessment is done to identify the patients response to health
problems. During the nursing assessment phase, a comprehensive
information base is developed through a physical examination, nursing
history, medication history, and professional observation. Identifying
underlying pathologic conditions and assisting the physician in identifying
medical conditions is not part of the nursing process. Determining the
patients mental status is one part of the nursing assessment, but it is not the
primary purpose.
DIF: Cognitive Level: Comprehension
REF: dm 36 OBJ: 1 | 3 TOP: Nursing
Process Step: Assessment
MSC: NCLEX Client Needs Category: Health Promotion and Maintenance
• What is the basis of the NANDA I taxonomy?
A. Functional health patterns
B. Human response patterns
C. Basic human needs
D. Pathophysiologic needs
ANS: B
The NANDA I taxonomy identifies human response patterns.
Functional components of health patterns are limited to activity, fluid
volume, nutrition, self care, and sensory perception. Basic human needs
comprise less than merely health patterns. Pathophysiologic needs are not
part of the scope of NANDA I.